IRIS Ultimaster Cohort in the IRIS-DES Registry

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-07-20

Study Completion Date

2024-07-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the relative effectiveness and safety of Ultimaster stent compared to other drug eluting stents.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

real world data percutaneous coronary intervention drug eluting stent

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ultimaster stent

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ultimaster stent

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 19 and more
* Intervention with Ultimaster stent
* Agreed with written informed consent form

Exclusion Criteria

* Intervention with Ultimaster stent and other drug eluting stent at the same time
* Life expectancy of 1year and under
* Cardiac shock

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Duk-Woo Park, MD

Sponsor-investigator

Responsibility Role SPONSOR_INVESTIGATOR

Wŏnju, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AMCCV2016-05

Identifier Type: -

Identifier Source: org_study_id

IRIS Ultimaster Cohort in the IRIS-DES Registry

Study Results

Basic Information

Brief Summary

Detailed Description

Conditions

Keywords

Study Design

Study Groups

Ultimaster stent

Ultimaster stent

Interventions

Ultimaster stent

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

CardioVascular Research Foundation, Korea

Duk-Woo Park, MD

Responsible Party

Duk-Woo Park, MD

Locations

Sejong General hospital

Gangwon National Univ. Hospital

Daegu Catholic University Medical Center

Keimyung University Dongsan Medical Center

Gangneung Asan Hospital

Inje University Ilsan Paik Hospital

Kwangju Christian Hospital

Pusan National University Hospital

Asan Medical Center

The Catholic Univ. of Korea Seoul St. Mary's hospital

The Catholic University of Korea St. Paul's Hospital

The Catholic University of Korea, Yeouido St. Mary's Hospital

The Catholic University of Korea St. Vincent's Hospital

Ulsan University Hospital

Wonju Severance Christian Hospital

Countries

Other Identifiers

AMCCV2016-05